EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis

Fadi G Haddad, Elias Jabbour, Koji Sasaki, Samuel Black, Jonathan Michael Savoy, Yesid Alvarado, Gautam Borthakur, Naveen Pemmaraju, Musa Yilmaz, Sara Delasalla, Ghayas C Issa, Hagop Kantarjian

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2026.02.013 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Fadi G Haddad und 11 weiteren Autor:innen. Beteiligte Einrichtung: MD Anderson Cancer Center, Department of Leukemia, The University of Texas, Houston, TX. Electronic address: fhaddad@mdanderson.org. Hauptthemen laut MEDLINE: Dasatinib, Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dasatinib is approved at 100 mg/d for newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). We report outcomes with frontline dasatinib 50 mg/d in a large cohort of patients with CML-CP. METHODS: In a phase II clinical trial, patients with newly diagnosed CML-CP received dasatinib 50 mg/d alone (n = 83) or in combination with venetoclax (n = 66). We evaluated the molecular response rates, incidence of adverse events, event-free survival (EFS), and overall survival (OS). RESULTS: One hundred forty-nine patients were included; the median age at diagnosis was 46.7 years (range, 19.9-84.3); Sokal risk was high-risk in 7 patients (4.7%). By 60 months of dasatinib therapy, the cumulative rates of major molecular response, MR4, and MR4.5 were 95%, 87%, and 86%, respectively. With a median follow-up of 73 months, the 5-year EFS and OS rates were 96% and 98%, respectively. Adverse events were observed in 72 patients (48%), including pleural effusion in 19 (12.7%), of which 3 (2%) of Grade 3. Eighteen patients (12%) discontinued dasatinib due to adverse events. CONCLUSION: The long-term follow-up confirms the safety and efficacy of dasatinib 50 mg/d in patients with newly diagnosed CML-CP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibProtein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAntineoplastic AgentsHumansFemaleMaleAgedMiddle AgedAdultAged, 80 and overTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

Chronic myeloid leukemiaPleural effusionResponseToxicityTyrosine kinase inhibitor

Substanzen

DasatinibProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • MD Anderson Cancer Center, Department of Leukemia, The University of Texas, Houston, TX. Electronic address: fhaddad@mdanderson.org.
  • MD Anderson Cancer Center, Department of Leukemia, The University of Texas, Houston, TX.
  • Department of Internal Medicine, Baylor College of Medicine, Houston, TX.

Förderung

  • NCI NIH HHS
  • NIH
  • National Cancer Institute

Zitieren

APA

Haddad, F. G., Jabbour, E., Sasaki, K., Black, S., Savoy, J. M., Alvarado, Y., Borthakur, G., Pemmaraju, N., Yilmaz, M., Delasalla, S., Issa, G. C., & Kantarjian, H. (2026). Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.02.013

Vancouver

Haddad FG, Jabbour E, Sasaki K, Black S, Savoy JM, Alvarado Y, et al. Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.02.013

BibTeX
@article{Haddad2026,
  author = {Haddad, Fadi G and Jabbour, Elias and Sasaki, Koji and Black, Samuel and Savoy, Jonathan Michael and Alvarado, Yesid and Borthakur, Gautam and Pemmaraju, Naveen and Yilmaz, Musa and Delasalla, Sara and Issa, Ghayas C and Kantarjian, Hagop},
  title = {Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.02.013}
}
Kostenlos starten →